FARR STEPHEN J 4
4 · ZOGENIX, INC. · Filed Jun 29, 2020
Insider Transaction Report
Form 4
ZOGENIX, INC.ZGNX
FARR STEPHEN J
DirectorPresident and COO
Transactions
- Exercise/Conversion
Common Stock
2020-06-25+27,500→ 93,355 total - Exercise/Conversion
Restricted Stock Units
2020-06-25−27,500→ 0 total→ Common Stock (27,500 underlying) - Tax Payment
Common Stock
2020-06-25$28.12/sh−13,635$383,416→ 79,720 total
Footnotes (5)
- [F1]The Restricted Stock Units (RSUs) were granted on March 14, 2017, with 100% of the RSUs to vest upon approval of the Company's New Drug Application (NDA) by the U.S. Food and Drug Administration for Fintepla. The NDA was approved on June 25, 2020.
- [F2]Includes 604 shares acquired under the Company's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
- [F3]Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of shares of RSUs described in footnote 1.
- [F4]Each RSU represents a contingent right to receive one share of ZGNX common stock.
- [F5]Not applicable.